ScholarLens Back to search
2018•Graefe s Archive for Clinical and Experimental OphthalmologyRequires access

A pharmacoepidemiologic study of ranibizumab and aflibercept use 2013–2016. The Fight Retinal Blindness! Project

the Fight Retinal Blindness Study Group, Daniel Barthelmes, Vuong Nguyen, Richard I. Walton, Mark Gillies, Vincent Daïen

Open publisher page 13 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 13 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Ranibizumab, Aflibercept, Medicine, Macular degeneration, Ophthalmology, Bevacizumab, Surgery, Chemotherapy

Related papers

Related paper 1Related paper 2
Back to paper searchBrowse research topicsOriginal source
A pharmacoepidemiologic study of ranibizumab and aflibercept use 2013–2016. The Fight Retinal Blindness! Project — Research Paper | ScholarLens